About Lupin Limited
Lupin Limited (LUPIN) has been publicly traded since 2001, making it a 25-year-old public company. It operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. The company is headquartered in Mumbai, India and employs approximately 24,006 people. With a market capitalization of $1.1 trillion, LUPIN is one of the largest publicly traded companies.
Key Statistics
- Current Price
- ₹2,314.90
- Market Cap
- ₹1.06T
- 52-Week High
- ₹2,377.60
- 52-Week Low
- ₹1,795.20
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
₹1,000 Invested
Monthly Returns Heatmap
Annual Returns
| Year | Return | Start | End |
|---|---|---|---|
| 2026 | +9.74% | ₹2,109.50 | ₹2,314.90 |
| 2025 | -9.89% | ₹2,341.14 | ₹2,109.50 |
| 2024 | +78.84% | ₹1,309.03 | ₹2,341.14 |
| 2023 | +81.09% | ₹722.86 | ₹1,309.03 |
| 2022 | -22.35% | ₹930.91 | ₹722.86 |
| 2021 | -2.13% | ₹951.16 | ₹930.91 |
| 2020 | +28.79% | ₹738.56 | ₹951.16 |
| 2019 | -8.99% | ₹811.52 | ₹738.56 |
| 2018 | -4.02% | ₹845.52 | ₹811.52 |
| 2017 | -40.08% | ₹1,411.14 | ₹845.52 |
| 2016 | -18.71% | ₹1,735.89 | ₹1,411.14 |
| 2015 | +29.18% | ₹1,343.81 | ₹1,735.89 |
| 2014 | +58.19% | ₹849.47 | ₹1,343.81 |
| 2013 | +48.64% | ₹571.50 | ₹849.47 |
| 2012 | +37.87% | ₹414.54 | ₹571.50 |
| 2011 | -6.59% | ₹443.80 | ₹414.54 |
| 2010 | +64.83% | ₹269.25 | ₹443.80 |
| 2009 | +141.94% | ₹111.29 | ₹269.25 |
| 2008 | -0.42% | ₹111.76 | ₹111.29 |
| 2007 | +3.34% | ₹108.15 | ₹111.76 |
| 2006 | +61.53% | ₹66.95 | ₹108.15 |
| 2005 | +12.13% | ₹59.71 | ₹66.95 |
| 2004 | +98.19% | ₹30.13 | ₹59.71 |
| 2003 | +144.63% | ₹12.32 | ₹30.13 |
| 2002 | +60.71% | ₹7.66 | ₹12.32 |
Valuation
LUPIN currently trades at a trailing P/E ratio of 22.8, which is considered moderate relative to the broader market. The forward P/E of 23.7 suggests analysts expect earnings to be higher in the coming year. The price-to-book ratio stands at 5.4. The price-to-sales ratio is 4.0.
Dividends
Lupin Limited pays a dividend to shareholders with a current yield of 0.52%. This translates to $12.00 per share annually. The payout ratio of 12% indicates sustainable dividend coverage.
Risk & Volatility
LUPIN has a beta of 0.31, indicating it is less volatile than the overall market. The stock's 52-week range is $1795.20 to $2377.60, and it currently trades near its 52-week high.
Analyst Ratings
Based on 37 analyst opinions, LUPIN has a consensus "buy" rating. The average price target of $2429.05 suggests 4.9% upside from current levels.
Frequently Asked Questions
What does Lupin Limited do? ▼
Lupin Limited is a Drug Manufacturers - Specialty & Generic company operating in the Healthcare sector. The company is headquartered in Mumbai, India.
What sector is LUPIN in? ▼
LUPIN operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
When did LUPIN go public? ▼
Lupin Limited went public in 2001, making it a 25-year-old public company as of 2026.
How much would $1,000 invested in LUPIN 5 years ago be worth today? ▼
A $1,000 investment in LUPIN five years ago would be worth approximately $2,246 today, representing a 124.6% return.
Does LUPIN pay dividends? ▼
Yes, Lupin Limited pays a dividend with a current yield of 0.52%, which is $12.0 per share annually.
What is LUPIN's market cap? ▼
Lupin Limited has a market capitalization of $1.1 trillion, classifying it as a mega-cap company.
What is LUPIN's P/E ratio? ▼
LUPIN has a trailing P/E ratio of 22.8 and a forward P/E of 23.7, which measures how much investors are paying per dollar of earnings.
Is LUPIN a buy, hold, or sell? ▼
Based on 37 opinions, LUPIN has a consensus "buy" rating. The average price target is $2429.05.
Last updated: 3/14/2026